Skip to main content

Table 2 In vitro and in vivo treatment efficacy of SN38 and irinotecan.

From: In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis

Xenografts

In vitro TCA SN38 IC50 (µg/mL)

In vivo treatment

Mean relative TV ± SEM (d 25 versus d 0)

TGI (%)

P

2

0.06

Control

13.1 ± 3.4

—

0.0095

Irinotecan

1.1 ± 0.1

92

17

21.2

Control

5.6 ± 0.3

—

0.028

Irinotecan

1.3 ± 0.1

77

21

0.001

Control

3.8 ± 0.5

—

0.028

Irinotecan

1.3 ± 0.1

66

22

25.2

Control

6.0 ± 1.9

—

0.028

Irinotecan

1.1 ± 0.1

82

36 T

0.008

Control

13.7 ± 1.8

—

0.0015

Irinotecan

0.20 ± 0.02

98

36 M1

17.0

Control

19.2 ± 7.4

—

0.0060

Irinotecan

1.4 ± 0.7

93

36 M3

0.035

Control

10.6 ± 1.5

—

0.0025

Irinotecan

0.4 ± 0.1

96

  1. The efficacy of SN38 in vitro is reported as the IC50 value observed in tumor clonogenic assays (TCAs). For the evaluation of irinotecan efficacy in vivo, xenografted mice where treated with irinotecan 40 mg/kg q5dx5. Mean relative tumor volume (TV) ± SEM (n = 8–10 tumors) calculated at d 25 versus d 0 are indicated with the corresponding tumor growth inhibition (TGI) value and statistical P value (Mann-Whitney test).
Back to article page

Molecular Medicine

ISSN: 1528-3658